Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US1510201049
Ticker CELG
Company CELGENE
Currency $
Price
Aware Investor Index (AII) 0.7795
Recommendation BUY
P/E 44.56
ROE 18.62 %
Capitalization 57,433,874,000 $
Dividend Yield 0.00 %
P/S 4.42
AII Position 265
P/E Position 573
ROE Position 169
Capitalization Position 145
Dividend Yield Position 595
Sales 13,003,000,000 $
10-Year Average Earnings 1,288,873,600 $
Shares Outstanding 808,700,000
Equity 6,921,000,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
CELGENE Investor Relations Web Site http://ir.celgene.com







Sales:

YEAR MONTH AMOUNT
2017 12 13,003,000,000.00 $
2016 12 11,229,000,000.00 $
2015 12 9,256,000,000.00 $
2014 12 7,670,400,000.00 $
2013 12 6,493,900,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 2,940,000,000.00 $
2016 12 1,999,000,000.00 $
2015 12 1,602,000,000.00 $
2014 12 1,999,900,000.00 $
2013 12 1,449,900,000.00 $
2012 12 1,456,180,000.00 $
2011 12 1,318,150,000.00 $
2010 12 880,512,000.00 $
2009 12 776,747,000.00 $
2008 12 -1,533,653,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 6,921,000,000.00 $
2016 12 6,600,000,000.00 $
2015 12 5,919,000,000.00 $
2014 12 6,524,800,000.00 $
2013 12 5,589,900,000.00 $
2012 12 5,694,467,000.00 $
2011 12 5,512,727,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 808,700,000
2016 12 803,300,000
2015 12 824,900,000
2014 12 836,000,000
2013 12 430,300,000
2012 12 440,796,000
2011 12 422,987,284

 












Bloomberg News for CELGENE:



Google News for CELGENE:

Financial Mercury - 5 hours ago
Is Celgene Corporation (CELG) Still Worth A Bite?
Shares of Celgene Corporation (NASDAQ:CELG) recorded -4.05% loss during trading session on November 12th, 2018. The script traded as ...
Marea Informative (blog)
Celgene: Money Will Flow Back
The good news for Celgene (CELG) is that a lot of the weakness in the stock over the last three months is related to general biotech sector ...
Fairfield Current
Celgene (CELG) Outpaces Stock Market Gains: What You Should ...
Celgene (CELG) closed at $75.09 in the latest trading session, marking a +1.1% move from the prior day. The stock outpaced the S&P 500's ...
Nyse Nasdaq News (press release)
Celgene (CELG) Q3 2018 Results - Earnings Call Transcript
Celgene Corp. (NASDAQ:CELG) Q3 2018 Earnings Call October 25, 2018 9:00 AM ET. Executives. Nina Goworek - Celgene Corp.
Seeking Alpha - 5 days ago
Why Celgene's Stock Nosedived in October
Shares of the blue-chip biotech giant Celgene Corp. (NASDAQ:CELG) sank by a worrisome 20.3% in October, according to S&P Global Market ...
Yahoo Finance - 6 days ago
Brief Take On Why I Like Celgene
Celgene (NASDAQ:CELG) is an integrated global biotechnology company focusing on the research and development (and commercialization) ...
Seeking Alpha - 25 Oct 2018
Does Celgene Tickle Your Buygene?
That's what I thought, and probably a lot of my fellow investors with me, when Celgene (CELG) announced that the FDA refused to review its ...
Simply Wall St
BidaskClub Lowers Celgene (CELG) to Strong Sell
BidaskClub cut shares of Celgene (NASDAQ:CELG) from a sell rating to a strong sell rating in a report issued on Saturday. A number of other ...
Motley Fool
In Depressed situation:: Celgene Corporation, (NASDAQ: CELG)
Celgene Corporation institutional ownership is held at 76.9% while insider ownership was 0.1%. As of now, CELG has a P/S, P/E and P/B ...
FDA Headlines
Celgene (CELG) Tops Q3 Sales & Estimates
Summit, NJ based Celgene CorporationCELG is a biopharmaceutical company focused on the discovery, development and commercialization ...


Back